Sharh maqola

CircRNA: A new class of targets for gastric cancer drug resistance therapy

Ying ZhengDepartment of Biochemistry and Molecular Biology, Zhejiang Key Laboratory of Pathophysiology, Medical School of Ningbo University, Ningbo, ChinaZhe LiDepartment of Gastroenterology, The First Affiliated Hospital of Ningbo University, Ningbo, ChinaYao WangDepartment of Biochemistry and Molecular Biology, Zhejiang Key Laboratory of Pathophysiology, Medical School of Ningbo University, Ningbo, ChinaWanjiao ChenDepartment of Gastroenterology, The First Affiliated Hospital of Ningbo University, Ningbo, ChinaYifan LinDepartment of Gastroenterology, The First Affiliated Hospital of Ningbo University, Ningbo, ChinaJunming GuoDepartment of Biochemistry and Molecular Biology, Zhejiang Key Laboratory of Pathophysiology, Medical School of Ningbo University, Ningbo, ChinaGuoliang YeDepartment of Gastroenterology, The First Affiliated Hospital of Ningbo University, Ningbo, China

2023en

ABI

Annotatsiya

Gastric cancer (GC) is one of the most common malignancies worldwide. Patients with advanced GC need palliative care to ensure survival. This includes the use of chemotherapy agents, such as cisplatin, 5-fluorouracil, oxaliplatin, paclitaxel, and pemetrexed, as well as targeted agents. However, the emergence of drug resistance evidence in poor patient outcomes and poor prognosis is a motivation to determine the specific mechanism of drug resistance. Interestingly, circular RNAs (circRNAs) play an important part in the carcinogenesis and progression of GC and are involved in GC drug resistance. This review systematically summarizes the functions and mechanisms of circRNAs underlying GC drug resistance, especially chemoresistance. It also emphasizes that circRNAs can serve as promising targets for improving drug resistance and therapeutic efficacy.

Hali tarjima qilinmagan

Identifikatorlar

DOI: 10.3389/pore.2023.1611033

Iqtiboslar va manbalar

2 ta iqtibos0 ta foydalanilgan manba

Koʻrsatkichlar — AkademScholar